Tomahawk, WI 10/18/2013 (BasicsMedia) – Brief background

Situated in San Diego, California, and founded on April 14, 1997, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is one of the leading biopharmaceutical companies of the world. Outside United States, the company’s main operating centre providing manufacturing as well as commercial facility is in Zofingen, Switzerland. The company prides itself in making the best oral medications targeting the G-protein-coupled receptors (GPCRs). The US Food and Drug Administration (FDA) approved of the drug called lorcaserin on June 27, 2012, publicising and commercializing it with the brand name called BELVIQ in United States. Along with this the company also puts in deliberate effort to make other advanced drugs to address several other health issues. This company is a stiff competitor of VIVUS Inc., Roche Group, Orexigen Therapeutics, Inc. and GlaxoSmithKline Healthcare.

Prized Productions and latest news

Now that BELVIQ has gained an international reputation, the company is experiencing profit in heaps and bounds addressing issues related to obesity and overweight in adults. The company claims that BELVIQ production will be doubled by Eisai Inc. by December, expanding its productivity and incorporating more than four hundred sale specialists. This increased productivity will make Eisai, make BELVIQ accessible to more than sixty five thousand physicians in United States along with other potential clients like endocrinologists, gastrointestinal specialists, care providers and cardiovascular specialists. While there are thousand benefits that one can derive out of this medicine, the numerous safety informations have also been cited by the company, for instance, not consuming this while pregnant, BELVIQ slowing the heartbeat, slowing down memory, excess intake resulting in painful erections, weight loss, mental problems, and so on. In the BELVIQ developmental programme, the three stages of developing the Phase III program includes Behavioural modification and Lorcaserin for Overweight and Obesity Management (BLOOM), Behavioural modification and Lorcaserin Second Study for Obesity Management (BLOSSOM) and Behavioural modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus (BLOOM-DM). The other oral drugs introduced by Arena includes APD371, used for treating autoimmune diseases, APD371 which is supposed to be the company’s lead product, is intended to relieve pain, being an agonist of cannabinoid receptor 2 and APD811 introduced in October, 2012, for treating pulmonary arterial hypertension. Other oral drugs which still has not been approved by FDA and is still under experimentation are APD791, for treating arterial thrombosis, APD916 for treating pulmonary hypertension, APD597, Phase II for treating diabetes type 2 and Phase I of Niacin receptor for treating arteriosclerosis. The company also introduced a Phase I clinical trial for APD334 in April, 2013. GPR119 also aims at treating diabetes type 2 by targeting the beta cells found in the pancreas which causes insulin secretion as a result of increase in blood glucose. The company has recently claimed the completion of APD881’s Phase 1b clinical trial which aimed at treating PAH (pulmonary arterial hypertension). In the initial months of 2014, the company plans on initiating the Phase II for this drug. The company has recently withdrawn an application in European Union to promote its anti obesity drug which has resulted in the downfall of its shares to almost fifteen percent.

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.